Form D · Biotechnology
MUSTANG BIO, INC.
Worcester, MA · CIK 0001680048
Offering snapshot reported Jun 24, 2024 · SEC filing
- Reported sold
- $2.51M Offering amount: $2.51M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 19, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 24, 2024 | Initial | $2,513,139 | No comparison | 1 | SEC filing |
| Nov 3, 2023 | Initial | $4,742,942 | No comparison | 1 | SEC filing |
| Apr 12, 2017 | Initial | $416,000 | No comparison | 7 | SEC filing |
| Feb 15, 2017 | Amendment | $94,585,711 | $55,489,031vs Jan 13, 2017 | 1,086 | SEC filing |
| Jan 13, 2017 | Amendment | $39,096,680 | $4,109,599vs Jan 13, 2017 | 519 | SEC filing |
| Jan 13, 2017 | Amendment | $34,987,081 | $3,100,500vs Dec 13, 2016 | 437 | SEC filing |
| Dec 13, 2016 | Amendment | $31,886,581 | $12,351,397vs Nov 4, 2016 | 390 | SEC filing |
| Nov 4, 2016 | Amendment | $19,535,184 | $7,088,770vs Oct 17, 2016 | 222 | SEC filing |
| Oct 17, 2016 | Initial | $12,446,414 | No comparison | 133 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $176K
- Finders' fees
- $0
- Form D file number
- 021-516643
The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investor and placement agent in the private placement under Rule 506(b).
In connection with the registered direct offering concurrent with the private placement, the placement agent received $175,931 and warrants to purchase up to 367,800 shares of common stock exercisable at $0.5125 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 |
Source: Form D, filed Jun 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Adam J. Chill | Director |
| Neil Herskowitz | Director |
| Manuel B. Litchman, M.D. | Director, Executive |
| Eliot Lurier | Executive |
| James B Murphy | Executive |
| Lindsay A. Rosenwald | Director |
| Lindsay A. Rosenwald, M.D. | Director |
| Michael S. Weiss | Director |
| Michael J. Zelefsky, M.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
377 Plantation Street
Worcester, MA, 01605
Worcester, MA, 01605